A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of ABBV-157 in Healthy Volunteers and in Participants With Chronic Plaque Psoriasis
Public ClinicalTrials.gov record NCT03922607. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability of ABBV-157 in Healthy Volunteers and in Subjects With Chronic Plaque Psoriasis
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a study to evaluate pharmacokinetics (PK), safety and tolerability of ABBV-157 in healthy volunteers and in participants with chronic plaque psoriasis, and to evaluate the efficacy of ABBV-157 in the participants with psoriasis. This study consists of two substudies. Substudy 1 is a randomized, double-blind, placebo-controlled evaluation of multiple ascending oral doses of ABBV-157 in healthy adult volunteers. Substudy 2 is a randomized, double-blind, placebo-controlled study in which participants with moderate to severe chronic plaque psoriasis will be administered multiple oral doses of ABBV-157.
Study identification
- NCT ID
- NCT03922607
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 65 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 11, 2019 (Actual)
- Primary completion
- Apr 13, 2021 (Actual)
- Completion
- Apr 13, 2021 (Actual)
- Last update posted
- May 11, 2021
2019 – 2021
United States locations
- U.S. sites
- 10
- U.S. states
- 7
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Total Skin and Beauty Derm Ctr /ID# 222593 | Birmingham | Alabama | 35205 | — |
| Alliance Dermatology and MOHs /ID# 222622 | Phoenix | Arizona | 85032 | — |
| Anaheim Clinical Trials LLC /ID# 213645 | Anaheim | California | 92801-2658 | — |
| Dermatology Res. Assoc., CA /ID# 224980 | Los Angeles | California | 90045 | — |
| Providence Clinical Research /ID# 213339 | North Hollywood | California | 91606 | — |
| Advanced Medical Research /ID# 216090 | Sandy Springs | Georgia | 30328-6141 | — |
| Acpru /Id# 213639 | Grayslake | Illinois | 60030 | — |
| University of Pittsburgh MC /ID# 224699 | Pittsburgh | Pennsylvania | 15260 | — |
| PPD PH I Clinical Unit /ID# 213062 | Austin | Texas | 78744 | — |
| Center for Clinical Studies - Webster TX /ID# 217352 | Webster | Texas | 77598 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03922607, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 11, 2021 · Synced Oct 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03922607 live on ClinicalTrials.gov.